Investigational drug · Phase 2
Fixed cemiplimab
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Melanoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
12
Any phase or sponsor naming "Fixed cemiplimab"
First trial start
2024
Sep 18, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Fixed cemiplimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Melanoma
Largest trials
Live from ClinicalTrials.gov: studies naming "Fixed cemiplimab" as an intervention, largest first.
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT04590326 · 612 participants (planned) · Start Dec 8, 2020 · Primary completion Nov 8, 2028
Drug: REGN5668; Cemiplimab and 3 more · For: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer and 1 more
Sites: Duarte, California; Irvine, California; Orange, California · 28 sites in all
- A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)Pivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06246916 · 560 participants (planned) · Start Sep 9, 2024 · Primary completion Mar 22, 2027
Drug: fianlimab; cemiplimab and 1 more · For: Melanoma
Sites: Chandler, Arizona; Gilbert, Arizona; Tucson, Arizona · 113 sites in all
- A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 MelanomaPivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06190951 · 151 participants · Start Sep 18, 2024 · Primary completion Nov 2, 2026
Drug: cemiplimab; Fixed Dose Combination (FDC) cemiplimab+fianlimab and 1 more · For: Melanoma
Sites: La Jolla, California; Los Angeles, California; Newport Beach, California · 104 sites in all
- A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06769698 · 120 participants (planned) · Start Apr 14, 2026 · Primary completion Jun 4, 2028
Drug: FDC fianlimab+cemiplimab; Cemiplimab and 1 more · For: Head and Neck Squamous Cell Carcinoma (HNSCC)
Sites: Los Angeles, California; Orlando, Florida; Atlanta, Georgia · 38 sites in all
- A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A EpendymomaPivotal-lookingNot yet recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07567469 · 120 participants (planned) · Start Aug 31, 2026 · Primary completion Aug 27, 2032
Drug: Cemiplimab; Cemiplimab+Fianlimab Fixed Dose Combination (FDC) · For: High-Grade Glioma (HGG); Posterior Fossa-A Ependymoma
Immune-Onc TherapeuticsIndustry
NCT05054348 · 91 participants · Start Sep 30, 2021 · Primary completion Apr 29, 2024
Drug: IO-108; IO-108 + pembrolizumab combination therapy and 1 more · For: Solid Tumor, Adult
Sites: Tucson, Arizona; Beverly Hills, California; Lone Tree, Colorado · 24 sites in all
Montefiore Medical CenterAcademic, hospital or other
NCT06865339 · 76 participants (planned) · Start Aug 7, 2025 · Primary completion Aug 2027
Drug: Cemiplimab; Fianlimab and 1 more · For: NSCLC; Locally Advanced
Sites: The Bronx, New York
Thomas Jefferson UniversityAcademic, hospital or other
NCT05929664 · 70 participants (planned) · Start Jul 5, 2023 · Primary completion Jul 5, 2031
Drug: Cemiplimab; Fianlimab · For: Locally Advanced Basal Cell Carcinoma; Basal Cell Carcinoma
Sites: Miami, Florida; Philadelphia, Pennsylvania; Nashville, Tennessee
- Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon CancerNot yet recruiting
John Strickler, M.D.Academic, hospital or other
NCT07224022 · 24 participants (planned) · Start Mar 1, 2027 · Primary completion Dec 31, 2029
Drug: Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)] · For: Colon Cancer
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Melanoma
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- Intismeran autogeneV940, mRNA-4157Phase 310 trials
Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- IBI363Phase 37 trials
Innovent Biologics (Suzhou) Co. Ltd. · Melanoma, Colorectal Cancer, Resectable Stage II-III Non-small Cell Lung Cancer
- OH2Phase 36 trials
Binhui Biopharmaceutical Co., Ltd. · Melanoma, Solid Tumor, Gastrointestinal Cancer
- PucotenlimabHX008Phase 36 trials
Lepu Biopharma Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Melanoma, Hepatocellular Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Regeneron.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.